CNBC’s Jim Cramer sits down with CVS Health CEO David Joyner to discuss the company's investor day, how healthcare technology ...

CVS Health Corporation is rated a Buy with a strong turnaround driving industry-leading results. Learn more about CVS stock ...

CVS Health’s narrative has shifted with a slightly higher fair value estimate, nudging from about $91.50 to roughly $92.40 ...

The healthcare giant expects its turnaround efforts to pay off as it raised its full-year outlook and expects that momentum ...

CVS Health on Tuesday forecast 2026 profit above Wall Street estimates and this year's projected earnings, signalling steady ...

Citing topline data from its Phase 3 TRIUMPH-4, the Indiana-based drugmaker said that retatrutide, a GIP, GLP-1, and glucagon triple hormone receptor agonist, at the two highest doses led to ...

Medical experts say getting a yearly flu vaccination is the best way to prevent flu and its potentially serious complications ...

Fintel reports that on December 12, 2025, Bernstein maintained coverage of CVS Health (NYSE:CVS) with a Market Perform ...

CVS Health Stock Gains on Guidance Raise. How It Expects to Perform in 2025 and Beyond.

It’s part of a larger battle between Louisiana officials and big health care companies over prescription drug prices.

Given many Americans’ poor experiences with the healthcare system, CVS now hopes its new “engagement as a service” platform ...